Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Over the past decade, there has been significant improvement in the treatment cardiac diseases and symptomatic bradyarrhythmias with the development of leadless pacemaker systems. The Micra transcatheter pacemaker system has been shown to mitigate a lot of the complications associated with traditional pacing systems, which are notably skin pocket and lead-related complications. Numerous studies have shown the low complication rates associated with Micra procedure; however, there have been no specific guidelines or recommendations surrounding periprocedural anticoagulant therapy. This is important because a significant percentage of patients requiring pacemaker therapy have an indication for anticoagulation therapy as well. Multiple studies have shown the safety of uninterrupted anticoagulation during Micra implant, however, there is insufficient high-quality data to recommend periprocedural systemic use of anticoagulation. In this paper, we review the available data surrounding anticoagulation therapy in patients undergoing Micra implantation and the potential bleeding risks associated with this procedure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2022.09.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stent it and Forget it? Not in Kids: Endovascular Treatment of Traumatic Arterial Injuries in Adolescents.
J Pediatr Surg
September 2025
Department of Pediatric Surgery, McGovern Medical School, UTHealth Houston and Children's Memorial Hermann Hospital, Houston, TX, USA(†). Electronic address:
Background: Repair strategies for pediatric vascular injuries must consider vascular growth and intervention durability. Endovascular interventions are increasingly utilized in pediatrics, particularly in unstable patients or for injuries in surgically morbid regions. This study describes a single-center experience with endovascular stenting in adolescent pediatric trauma.
View Article and Find Full Text PDFEvaluation of Bleeding and Thrombotic Outcomes of Anticoagulation Strategies Upon Intensive Care Unit Admission for Patients with Atrial Fibrillation on Direct Oral Anticoagulants.
J Pharm Pract
September 2025
Department of Pharmacy, Houston Methodist Hospital, TX, USA.
Critically ill adults are more commonly being admitted to intensive care units (ICU) with a recent history of direct oral anticoagulant (DOAC) use. No consensus guidance exists on optimal anticoagulation strategies in critically ill adults with non-valvular atrial fibrillation (NVAF) on DOAC's prior to ICU admission, and there is considerable variability in clinical practice. To evaluate rates of major bleeding and thrombosis between 2 anticoagulation strategies for NVAF upon ICU admission: package insert (continuation of oral or parenteral anticoagulation per manufacturer recommendations) vs non-package insert (prophylactic dosing or delayed therapeutic anticoagulation).
View Article and Find Full Text PDFUtility of [Tc]Tc-tilmanocept, an immunosuppressive macrophage functional imaging agent in melanoma patients receiving checkpoint inhibitor treatment: a feasibility study.
Cancer Immunol Immunother
September 2025
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
Background: Immunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126).
View Article and Find Full Text PDFA 10-year review of iliofemoral deep vein thrombosis - are they more dangerous than their distal counterparts?
J Thromb Thrombolysis
September 2025
Department of Haematology, Northern Hospital, 185 Cooper St, Epping, VIC, 3076, Australia.
Iliofemoral deep vein thrombosis (IFDVT) is associated with potential for poor outcomes despite optimal anticoagulation therapy. To characterize the real-world management of IFDVT in an Australian population. Retrospective evaluation of IFDVT cases managed at Northern Health, Australia from January 2011 to December 2020 was performed and compared to non-iliofemoral lower limb DVTs (non-IFDVT) (n = 1793).
View Article and Find Full Text PDFImpact of drug utilization management strategies on the incidence and cost of clinical events in patients with non-valvular atrial fibrillation receiving DOACs in the US.
J Med Econ
September 2025
Health Economics and Outcomes Research Ltd., Cardiff, United Kingdom.
Background: Medicare plans employ drug utilization management strategies, including prior authorization (PA) and step therapy (ST), or formulary tier increases, to control spending. However, PA and ST can delay treatment access and encourage use of less effective/safe therapies, while formulary tier increases can lead to treatment switching/discontinuation due to higher patient out-of-pocket costs. This study modeled the impact of restricted access to direct oral anticoagulants (DOACs), and a tier increase for apixaban, on incidence and cost of clinical events in patients with non-valvular atrial fibrillation (NVAF) in the United States.
View Article and Find Full Text PDF